Invasion and metastasis are main traits of tumor progression and responsible for the poor prognosis of advanced non-small cell lung cancer (NSCLC). The molecular mechanisms underlying the malignant behaviors of NSCLC remain incompletely understood. The present study demonstrate that up-regulator of cell proliferation (URGCP), a recently identified tumor-promoting gene found in several tumor types, is markedly overexpressed in human NSCLC cell lines and clinical NSCLC samples. URGCP upregulation correlates significantly with the progression and poor prognosis of this disease. In vitro and in vivo studies demonstrate that increasing URGCP expression accelerates invasion, migration, and distant metastasis of NSCLC cells whereas downregulating URGCP suppresses these malignant traits. Notably, silencing URGCP expression almost completely abrogates the metastatic ability of NSCLC cells. At the molecular level, URGCP markedly promotes MMP-9 expression by activating NF-κB signaling. Additionally, URGCP and MMP-9 expression are positively correlated in various cohorts of human NSCLC specimens, and NF-κB-activated MMP-9 expression contributes to URGCP-induced invasiveness of NSCLC cell lines. Collectively, these findings indicate that URGCP plays an important role in promoting NSCLC cell invasion and metastasis by enhancing NF-κB-activated MMP-9 expression and may serve as a potential therapeutic target and prognostic marker.
URGCP promotes non-small cell lung cancer invasiveness by activating the NF-κB-MMP-9 pathway.
URGCP 通过激活 NF-κB-MMP-9 通路促进非小细胞肺癌的侵袭性
阅读:10
作者:Cai Junchao, Li Rong, Xu Xiaonan, Zhang Le, Wu Shanshan, Yang Tianyou, Fang Lishan, Wu Jueheng, Zhu Xun, Li Mengfeng, Huang Yongbo
| 期刊: | Oncotarget | 影响因子: | 0.000 |
| 时间: | 2015 | 起止号: | 2015 Nov 3; 6(34):36489-504 |
| doi: | 10.18632/oncotarget.5351 | 研究方向: | 细胞生物学 |
| 疾病类型: | 肺癌 | 信号通路: | NF-κB |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
